Mogamulizumab莫格利组单抗莫格利组单抗,1159

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Mogamulizumab

CAS No. : 1159266-37-1

MCE 国际站：Mogamulizumab

产品活性：Mogamulizumab (KW-0761) 是一种去岩藻糖基化的重组 抗 CCR4 单克隆抗体 (MAb)。Mogamulizumab 可以通过抗体依赖性细胞毒性 (ADCC) 消除肿瘤细胞。Mogamulizumab 可用于癌症、成人T细胞白血病/淋巴瘤 (ATLL)、皮肤T细胞淋巴瘤 (CTCL) 的研究。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CCR

In Vitro: Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs.
Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4⁺CCR4⁺ T cells in cultured PBMCs from patients with HAM/TSP.

In Vivo: Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model.
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model.
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4⁺CCR4⁺ T cells, with no adverse effect in dogs.

相关产品：Pirfenidone  |  Maraviroc  |  RS 504393  |  Bindarit  |  INCB3344  |  BX471  |  PF-4136309  |  RS102895 hydrochloride  |  Cenicriviroc  |  TAK-779  |  CCR6 inhibitor 1  |  Zelnecirnon  |  CCR6 antagonist 1  |  AZ084  |  ZK756326 dihydrochloride  |  AZD2098  |  GW 766994  |  R243  |  7,4'-Dihydroxyflavone  |  BMS-813160  |  CCR7 Ligand 1  |  MK-0812 Succinate  |  K777  |  Vercirnon  |  DAPTA  |  Tivumecirnon  |  C-021  |  CCR2 antagonist 4 hydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds